Italy Blood Glucose Monitoring Market Insights Forecasts to 2033

• The Italy Blood Glucose Monitoring Market Size was valued at USD 633.88 Million in 2023.
• The Market Size is Growing at a CAGR of 8.6% from 2023 to 2033
• The Italy Blood Glucose Monitoring Market Size is Expected to Reach USD 1449.35 Million by 2033

The Italy Blood Glucose Monitoring Market Size is Anticipated to Reach USD 1449.35 Million by 2033, Growing at a CAGR of 8.6% from 2023 to 2033

Market Overview

Blood glucose monitoring is the process of regularly measuring and checking the levels of glucose in your bloodstream. Individuals use blood glucose monitoring system devices to measure the amount of glucose in their blood. These devices are critical for patients with type 1 and 2 diabetes. One of the major factors contributing to the growing patient pool that requires regular monitoring of blood glucose levels is the increasing prevalence of diabetes in the general population around the world. The growing patient pool, as well as market players' increased efforts to develop and introduce new blood glucose monitoring systems with novel technologies, are expected to drive demand for these devices. The growing prevalence of diabetes, as well as the growing elderly population, have a significant impact on the market. Additionally, rising awareness of diabetes prevention measures, as well as the introduction of new products, are driving market growth. Diabetes, a widespread and growing global concern, is caused by the pancreas' inability to produce insulin efficiently, resulting in high blood glucose levels.

Report Coverage

This research report categorizes for the Italy blood glucose monitoring market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Italy blood glucose monitoring market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Italy blood glucose monitoring market.

Driving Factors

The rising prevalence of diabetes in both developed and developing countries is creating a large global patient pool that requires blood monitoring, which is driving up demand for these devices among patients. The use of these systems is rapidly expanding due to factors such as an increase in the number of diabetic patients, patients' increased knowledge of blood sugar monitoring, and the development of novel monitoring devices by major companies. Diabetes patients can benefit from blood glucose monitoring devices in four distinct ways. These devices facilitate therapy adjustments and patient protection by allowing patients and doctors to detect acute hyperglycemia or hypoglycemia while also empowering patients with increased self-care. Technology implementation encourages people to adopt healthier behaviors and makes it easier for patients to learn about diabetes and how to manage it. Another significant factor that is expected to increase the adoption of blood glucose monitoring systems and, as a result, drive market growth during the forecast period.

Restraining Factors

The increasing technological advancements in blood glucose monitoring devices, particularly CGM systems, are driving up their costs resulting in hampers the market growth.

Market Segmentation

The Italy blood glucose monitoring market share is classified into modality and patient type.

• The wearable segment is expected to hold the largest market share through the forecast period.

The Italy blood glucose monitoring market is segmented by modality into wearable and non-wearable. Among these, the wearable segment is expected to hold the largest market share through the forecast period. The segment's dominance can be attributed to an increasing number of product launches, which is expected to increase patient adoption of these devices.

• The type-2 diabetes segment is expected to dominate the Italy blood glucose monitoring market during the forecast period.       

Based on the patient type, the Italy blood glucose monitoring market is divided into type-1 diabetes and type-2 diabetes. Among these, the type-2 diabetes segment is expected to dominate the Italy blood glucose monitoring market during the forecast period. The segment's dominance can be attributed to the comparatively larger patient population with insulin-dependent type 2 diabetes. The growing patient pool, combined with increasing awareness of monitoring devices, is supporting the growing adoption of monitoring systems among patients.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Italy blood glucose monitoring market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Abbott Diabetes Care
• Roche Holding AG
• LifeScan
• Dexcom Inc.
• Medtronic PLC
• Arkray Inc.
• Ascensia Diabetes Care
• Agamatrix Inc.
• Bionime Corporation
• Acon Laboratories Inc.
• Trivida Functional Medicine
• Senseonics
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Recent Developments

• In August 2024, The Simplera is Medtronic's most recent continuous glucose monitor (CGM) for diabetics aged two and up. Simplera is an elegant, disposable device that eliminates the need for fingersticks. It is currently being evaluated by the FDA for approval in the United States. In Europe, Medtronic's most recent CGM, Simplera, has already been approved.

Market Segment

This study forecasts revenue at Italy, regional, and country levels from 2020 to 2033. Spherical Insights has segmented the Italy blood glucose monitoring market based on the below-mentioned segments:

Italy Blood Glucose Monitoring Market, By Modality

• Wearable
• Non-wearable

Italy Blood Glucose Monitoring Market, By Patient Type

• Type-1 Diabetes
• Type-2 Diabetes